SPCS2: A Potential Drug Target and Biomarker for ALS (G9789)

Target Name: SPCS2

NCBI ID: G9789

SPCS2

SPCS2: A Potential Drug Target and Biomarker for ALS

Spinal cord injury (SCI) is a devastating condition that affects millions of people worldwide, resulting in significant morbidity and mortality. SCI-related pain is a major cause of disability and can significantly impact a patient's quality of life. The development of pain is closely associated with the loss of motor and sensory function in the spinal cord, which is a result of the damage to the central nervous system (CNS) caused by SCI.

SPCS2, a 25 kDa subunit of microsomal signal peptidase, is a protein that is expressed in the spinal cord and is involved in the processing of motor and sensory signals. SPCS2 has been shown to play a crucial role in the development and progression of SCI- related pain.

SPCS2 functions as a scaffold protein, which helps to maintain the structural integrity of the neuronal cytoskeleton. It plays a vital role in the delivery of synaptic vesicles, which contain the neurotransmitter acetylcholine (ACh) to the dendrites of target neurons. In SCI, the loss of synaptic vesicles and the dysfunction of SPCS2 have been linked to the development of pain.

SPCS2 has also been shown to play a role in the regulation of pain modalities, including nociceptive pain and neuropathic pain. It has been shown to reduce the expression of pain-related genes in the spinal cord and to protect against the development of pain-refractory neurons.

SPCS2 has also been shown to be involved in the regulation of muscle tone and muscle spasticity. It has been shown to reduce the activity of the muscle tonic pathway, which is involved in maintaining muscle tone, and to increase the activity of the muscle relaxant pathway , which is involved in muscle spasticity.

SPCS2 has also been shown to play a role in the regulation of neurogenesis, which is the process by which new neurons are generated in the brain. It has been shown to promote the proliferation and differentiation of neural stem cells and to regulate the apoptosis (programmed cell death) of these cells.

SPCS2 has been shown to be involved in the regulation of axon growth, which is the process by which neurons extend their axons out of the CNS to innervate muscles and other tissues. It has been shown to promote the extension of axons and to reduce the fusion of axons, which is a critical step in the development of neural circuits.

SPCS2 has also been shown to play a role in the regulation of neurotransmitter release, which is the process by which neurotransmitters are released from the axon terminal of neurons and act on their targets. It has also been shown to regulate the release of neurotransmitters, including ACh, and to modulate the effects of neurotransmitters on target neurons.

SPCS2 has been shown to play a crucial role in the development and progression of SCI-related pain. It has been shown to contribute to the dysfunction of the CNS, which is responsible for the processing and interpreting sensory information.

SPCS2 has also been shown to play a role in the regulation of pain modalities, including nociceptive pain and neuropathic pain. It has been shown to reduce the expression of pain-related genes in the spinal cord and to protect against the development of pain-refractory neurons.

SPCS2 has also been shown to be involved in the regulation of muscle tone and muscle spasticity. It has been shown to reduce the activity of the muscle tonic pathway

Protein Name: Signal Peptidase Complex Subunit 2

Functions: Component of the signal peptidase complex (SPC) which catalyzes the cleavage of N-terminal signal sequences from nascent proteins as they are translocated into the lumen of the endoplasmic reticulum (PubMed:34388369). Enhances the enzymatic activity of SPC and facilitates the interactions between different components of the translocation site (By similarity)

The "SPCS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPCS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets